Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Pharm Res
2009 Mar 01;263:560-7. doi: 10.1007/s11095-008-9771-4.
Show Gene links
Show Anatomy links
Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp).
Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, Langguth P, Tamai I.
???displayArticle.abstract???
The purpose of this study is to clarify the impact of P-gp and Oatp on intestinal absorption of the beta(1)-adrenoceptor antagonist talinolol. P-gp-mediated transport was measured in LLC-PK1/MDR1 cells. Oatp-mediated uptake was evaluated with Xenopus oocytes expressing Oatp1a5. Rat intestinal permeability was measured by the in situ closed loop method. In vivo absorption was pharmacokinetically assessed by measuring plasma concentration after oral administration in rats. In LLC-PK1/MDR1 cells, the permeability of talinolol was markedly higher in the secretory direction than in the absorptive one. The uptake of talinolol by Xenopus oocytes expressing Oatp1a5 was significantly increased compared with that by water-injected oocytes. Naringin inhibited talinolol uptake by Oatp1a5 (IC (50) = 12.7 microM). The reported IC (50) value of naringin for P-gp-mediated transport of talinolol is approximately 2,000 microM. Rat intestinal permeability of talinolol was significantly decreased in the presence of 200 microM naringin, but was significantly increased by 2,000 microM naringin. Similar results were obtained in in vivo absorption studies in rats. The absorption behavior of talinolol can be explained by the involvement of both P-gp and Oatp, based on characterization of talinolol transport by Oatp1a5 and P-gp, and the effects of naringin.
???displayArticle.pubmedLink???
19002566 ???displayArticle.link???Pharm Res
Ambudkar,
Biochemical, cellular, and pharmacological aspects of the multidrug transporter.
1999, Pubmed
Ambudkar,
Biochemical, cellular, and pharmacological aspects of the multidrug transporter.
1999,
Pubmed Augustine,
Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier.
2005,
Pubmed Bailey,
Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice.
2007,
Pubmed de Castro,
Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells.
2007,
Pubmed De Castro,
Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies.
2006,
Pubmed Dresser,
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.
2002,
Pubmed Fagerholm,
Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms.
1997,
Pubmed Fromm,
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.
2000,
Pubmed Hanafy,
Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats.
2001,
Pubmed Hilgendorf,
Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport.
2005,
Pubmed Kikuchi,
Transporter-mediated intestinal absorption of fexofenadine in rats.
2006,
Pubmed
,
Xenbase Kobayashi,
Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane.
2003,
Pubmed Koitabashi,
Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects.
2006,
Pubmed Macheras,
Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity?
1997,
Pubmed Maeda,
Identification of influx transporter for the quinolone antibacterial agent levofloxacin.
2007,
Pubmed
,
Xenbase Masaoka,
Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract.
2006,
Pubmed Naruhashi,
Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.
2001,
Pubmed Nozawa,
Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human.
2004,
Pubmed Ofer,
Bidirectional membrane transport: simulations of transport inhibition in uptake studies explain data obtained with flavonoids.
2006,
Pubmed Schinkel,
P-Glycoprotein, a gatekeeper in the blood-brain barrier.
1999,
Pubmed Schwarz,
Grapefruit juice ingestion significantly reduces talinolol bioavailability.
2005,
Pubmed Schwarz,
Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
1999,
Pubmed Schwarz,
P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
2000,
Pubmed Shirasaka,
Scaling of in vitro membrane permeability to predict P-glycoprotein-mediated drug absorption in vivo.
2008,
Pubmed Shirasaka,
Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane.
2008,
Pubmed Shitara,
Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.
2002,
Pubmed Spahn-Langguth,
Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol.
2001,
Pubmed Spahn-Langguth,
P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
1998,
Pubmed Tamai,
Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.
2000,
Pubmed Tamai,
Nonlinear intestinal absorption of 5-hydroxytryptamine receptor antagonist caused by absorptive and secretory transporters.
1997,
Pubmed Tani,
Involvement of organic anion transporting polypeptide 1a5 (Oatp1a5) in the intestinal absorption of endothelin receptor antagonist in rats.
2008,
Pubmed
,
Xenbase Tanigawara,
Role of P-glycoprotein in drug disposition.
2000,
Pubmed Tourniaire,
Molecular mechanisms of the naringin low uptake by intestinal Caco-2 cells.
2005,
Pubmed Trausch,
Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man.
1995,
Pubmed Tsuji,
Carrier-mediated intestinal transport of drugs.
1996,
Pubmed Verschraagen,
P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.
1999,
Pubmed Walters,
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
2000,
Pubmed Weitschies,
The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.
2005,
Pubmed Westphal,
Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
2000,
Pubmed Wetterich,
Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.
1996,
Pubmed Yu,
The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
1999,
Pubmed Zhou,
Pharmacokinetic strategies in deciphering atypical drug absorption profiles.
2003,
Pubmed Zschiesche,
Stereoselective disposition of talinolol in man.
2002,
Pubmed
